Mayne Pharma Group Ltd (ASX:MYX)
A$ 5.1 0.67 (15.12%) Market Cap: 433.88 Mil Enterprise Value: 323.42 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 74/100

Full Year 2020 Mayne Pharma Group Ltd Earnings Call Transcript

Aug 20, 2020 / 11:00PM GMT
Release Date Price: A$7 (+1.45%)
Operator

Good day, ladies and gentlemen, and welcome to the Mayne Pharma Group Limited Results Full Year Call. At this time, I'd like to turn the conference over to Mr. Scott Richards. Please go ahead, sir.

Scott Anthony Richards
Mayne Pharma Group Limited - MD, CEO & Executive Director

Thank you and good morning, everybody. Thank you for joining us today to discuss Mayne Pharma's Full Year 2020 Financial Results. I'm joined on the call by Peter Paltoglou, our Interim CFO and Chief Development Officer. What I'd like to do this morning is give you a brief update on the business and how our operating segments have performed and together with an update on our pipeline and strategic growth plans. Pete will then provide some additional details on our financial results. And then we will open up the call to questions.

First of all, despite the challenges of COVID-19, our 2 key sites in Greenville and Salisbury have been fully operational, and our external supply partners have serviced us well. As a pharmaceutical business, we have a critical role during the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot